Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca To Share FibroGen’s Anemia Compound With Astellas, But Will Hoard China For Itself

This article was originally published in PharmAsia News

Executive Summary

In FibroGen’s FG-4592, AstraZeneca sees a potential strong seller in China where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.

You may also be interested in...



The Other Fish In The Sea: AstraZeneca Buys Omthera

AstraZeneca agreed to pay $260 million plus contingency payments to acquire Omthera, the makers of the omega-3 product Epanova, which is ready for regulatory filing for dyslipidemia. The deal raises questions for Amarin, whose similar product Vascepa has reached the market without a big pharma partner.

AstraZeneca Makes Good On Vow To Build CV Pipeline With AlphaCore Buy

AstraZeneca’s biologics unit MedImmune acquired AlphaCore Pharma, the developer of an early-stage asset with a novel mechanism for removing cholesterol from the body and raising “good” HDL cholesterol.

Revamping AstraZeneca, Soriot Calls For Focus And Speedier Innovation

AstraZeneca will accelerate development of several mid-stage assets into Phase III and turn aggressively to business development under CEO Pascal Soriot’s strategy to transform the company, even as it shores up its P&L with more job cuts.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC085202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel